SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Open for collaboration: an academic platform for drug discovery and development at SciLifeLab
8 references·2 citing·35 second hop
Open for collaboration: an academic platform for drug discovery and development at SciLifeLab (2016)Open for collaboration: an academic platf…Mitigating risk in academic preclinical drug discovery (2015)Mitigating risk in academic p…Academic drug discovery centres: the economic and organisational sustainability of an emerging model (2014)Academic drug discovery centr…UK academic drug discovery (2013)UK academic drug discoveryBringing together the academic drug discovery community (2013)Bringing together the academi…US academic drug discovery (2011)US academic drug discoveryThe Role of Public-Sector Research in the Discovery of Drugs and Vaccines (2011)The Role of Public-Sector Res…Believe it or not: how much can we rely on published data on potential drug targets? (2011)Believe it or not: how much c…The importance of new companies for drug discovery: origins of a decade of new drugs (2010)The importance of new compani…Doing science together: Gaining momentum from long-term explorative university–industry research programs (2023)Doing science together: Gaini…Open innovation in neuroscience research and drug discovery (2018)Open innovation in neuroscien…Lessons from 60 years of pharmaceutical innovation (2009)Racing to define pharmaceutical R&D external innovation models (2014)Academic–Industrial Collaboration: Toward the Consilience of Two Solitudes (2015)Ten Years of Medicinal Chemistry (2005–2014) in the Journal of Medicinal Chemistry: Country of Contributors, Topics, and Public–Private Partnerships (2016)Priorities in Scientific Discovery: A Chapter in the Sociology of Science (1957)Toward a new economics of science (1994)Picking winners or building them? Alliance, intellectual, and human capital as selection criteria in venture financing and performance of biotechnology startups (2003)How Much Longer Will We Put Up With $100,000 Cancer Drugs? (2017)The endless frontier? The recent increase of R&D productivity in pharmaceuticals (2020)Academic drug discovery: Challenges and opportunities (2024)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Investigating the factors that diminish the barriers to university–industry collaboration (2010)Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data (2016)Pharmaceutical Industry, Academia, Regulatory Authorities and End User Collaboration in Successful Drug Discovery and Development (2021)The price of innovation: new estimates of drug development costs (2003)The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs (2015)Public sector financial support for late stage discovery of new drugs in the United States: cohort study (2019)Why Most Published Research Findings Are False (2005)Increasing value and reducing waste in research design, conduct, and analysis (2014)The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta‐analyses (2016)Evaluating the replicability of social science experiments in Nature and Science between 2010 and 2015 (2018)Regional advantage: culture and competition in Silicon Valley and Route 128 (1994)The New Argonauts. Regional Advantage in a Global Economy (2009)Orphan drug development: an economically viable strategy for biopharma R&D (2012)Asymmetric Growth and Institutions in an Interdependent World (2017)Open Innovation: The New Imperative For Creating and Profiting From Technology (2004)Making Innovation Work: How to Manage It, Measure It, and Profit from It (2007)Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014)Absorptive Capacity: A New Perspective on Learning and Innovation (1990)Academic engagement and commercialisation: A review of the literature on university–industry relations (2012)Seeking Qualitative Rigor in Inductive Research (2012)Open innovation in early drug discovery: roadmaps and roadblocks (2015)The academic–industrial complex: navigating the translational and cultural divide (2017)Trait and state biomarkers for psychiatric disorders: Importance of infrastructure to bridge the gap between basic and clinical research and industry (2018)Academic drug discovery within the United Kingdom: a reassessment (2015)
this work references cited by second hop

References

  • 2011Believe it or not: how much can we rely on published data on potential drug targets?1,885 cited
  • 2010The importance of new companies for drug discovery: origins of a decade of new drugs344 cited
  • 2011The Role of Public-Sector Research in the Discovery of Drugs and Vaccines245 cited
  • 2015Mitigating risk in academic preclinical drug discovery188 cited
  • 2011US academic drug discovery101 cited
  • 2013Bringing together the academic drug discovery community60 cited
  • 2013UK academic drug discovery32 cited
  • 2014Academic drug discovery centres: the economic and organisational sustainability of an emerging model25 cited

Cited by

  • 2018Open innovation in neuroscience research and drug discovery6 cited
  • 2023Doing science together: Gaining momentum from long-term explorative university–industry research programs6 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work